Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5469-5473

  Lloyd, John ^a   Finlay, Heather J ^a   Atwal, Karnail ^a   Kover, Alexander ^a   Prol, Joseph ^a   Yan, Lin ^a   Bhandaru, Rao ^a   Vaccaro, Wayne ^a   Huynh, Tram ^a   Huang, Christine S ^a   Conder, MaryLee ^a   Jenkins West, Tonya ^a   Sun, Huabin ^a   Li, Danshi ^a   Levesque, Paul ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atrial fibrillation; IKur; KV1.5; Voltage gated potassium channel

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; PYRAZOLOPYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; PHARMACODYNAMICS; RABBIT; RAT;

ANIMALS; ATRIAL FIBRILLATION; CELL LINE; HUMANS; KV1.5 POTASSIUM CHANNEL; MICE; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; PYRIMIDINES; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 68949103853     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.083     Document Type: Article

References (13)

1. Wattigney W.A., Mensah G.A., and Croft J.B. Circulation 108 (2003) 711-716
2. Feinberg W.M., Blackshear J.L., Laupacais A., et al. Arch. Intern. Med. 155 (1995) 469-473
3. Go A.E., Hylek E.M., Phillips K.A., Chang Y.-C., Henault L.E., Selby J.V., and Singer D.E. J. Am. Med. Assoc. 285 (2001) 2370-2375
4. Wolf P.A., Mitchell J.B., Baker C.S., et al. Arch. Intern. Med. 158 (1998) 229-234
5. Amos G.J., Wettwer E., Li Q., Himmel H.M., and Ravens U. Circulation 90 (1994) I-581a
6. Li G.R., Feng J., Yue L., Carrier M., and Nattel S. Circ. Res. 78 (1996) 689-696
7. Yang T., Snyders D., and Roden D. J. Cardiovasc. Pharm. 38 (2001) 737-744
8. Wang Z., Fermini B., and Nattel S. Circ. Res. 73 (1993) 1061-1076
9. Feng J., Wible B., Li G.R., Wang Z., and Nattel S. Circ. Res. 80 (1997) 572-579
10. Vacarro W., Huynh T., Lloyd J., Atwal K.S., Finlay H.J., Levesque P.C., Conder M.L., Jenkins-West T., Shi H., and Sun L. Bioorg. Med. Chem. Lett. I18 (2008) 6381-6385
11. Snyders D.J., Tamkun M.M., and Bennet P.B. J. Gen. Physiol. 101 (1993) 513-543
12. dss) were calculated after intra-arterial administration. The absolute oral bioavailability (F, expressed as%) was estimated by taking the ratio of dose-normalized AUC value after an oral dose to that after an intra-arterial dose.
13. Sun H., Lloyd J., Shi H., Li D., and Levesque P. Heart Rhythm. 5 (2008) S213